Equity Overview
Price & Market Data
Price: $120.0
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $1,718,068,480
Daily Volume: 0
Performance Metrics
1 Week: 8.47%
1 Month: -10.69%
3 Months: 35.72%
6 Months: 82.47%
1 Year: 498.1%
YTD: 14.67%
Company Details
Employees: 29
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.